Home

Elisabeth Sandoval Little

CIK 1632295 · CCO & EVP, Corporate Strategy · last filed 2026-06-10

Elisabeth Sandoval Little is a CCO & EVP, Corporate Strategy who has filed 32 SEC Form 4 insider transactions across 7 companies since 2015. The most recent filing, for PRCT, was dated Jun 10, 2026. Across all open-market trades the lifetime net is −$6.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $306.4K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$306.4K

Companies

7

Total Filings

32

Lifetime Open-Market Net

-$6.51M

Filer Profile

Reported Address
C/O KYTHERA BIOPHARMACEUTICALS, INC.
30930 RUSSELL RANCH ROAD, 3RD FLOOR
WESTLAKE VILLAGE, CA 91362
Formerly Known As
Sandoval Elisabeth (2015–2025)
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
PRCT Director 15,876 $19.30 $306.4K $0 6 2026-06-10
VYNE Therapeutics Inc. (VYNE) Delisted Director — $28.56 — $0 6 2025-12-15
Satsuma Pharmaceuticals, Inc. (STSA) Delisted Director — $1.10 — $0 4 2023-06-08
Intersect ENT, Inc. (XENT) Delisted Director — $28.24 — $0 2 2022-05-16
VYNE Therapeutics Inc. (MNLO) Delisted Director — — — $0 4 2020-08-05
ALDER BIOPHARMACEUTICALS INC (ALDR) Delisted CCO & EVP, Corporate Strategy — — — $0 4 2018-02-21
KYTHERA BIOPHARMACEUTICALS INC (KYTH) Delisted Chief Commerical Officer 0 — — -$6.51M 6 2015-10-02

Recent Filings

32 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-10 PRCT Grant (A) +3,315 $0 EDGAR
2025-12-15 VYNE Therapeutics Inc. (VYNE) Delisted Grant (A) — $0 EDGAR
2025-06-12 PRCT Grant (A) +1,538 $0 EDGAR
2024-12-13 VYNE Therapeutics Inc. (VYNE) Delisted Grant (A) — $0 EDGAR
2024-06-06 PRCT Grant (A) +1,376 $0 EDGAR
2024-01-03 VYNE Therapeutics Inc. (VYNE) Delisted Grant (A) — $0 EDGAR
2023-12-15 VYNE Therapeutics Inc. (VYNE) Delisted Grant (A) — $0 EDGAR
2023-06-16 PRCT Grant (A) +2,711 $0 EDGAR
2023-06-08 Satsuma Pharmaceuticals, Inc. (STSA) Delisted Disp (D) — $0 EDGAR
2022-08-12 VYNE Therapeutics Inc. (VYNE) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 32
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.